Passive transfer of serum antibodies induced by BBG2Na, a subunit vaccine, in the elderly protects SCID mouse lungs against respiratory syncytial virus challenge

Virology

Volumn 303, Issue 1, 2002, Pages 130-137

  Plotnicky Gilquin, Hélène ^a   Cyblat Chanal, Dominique ^a   Goetsch, Liliane ^a   Lacheny, Christine ^a   Libon, Christine ^a   Champion, Thierry ^a   Beck, Alain ^a   Pasche, Hélène ^a   Nguyen, Thien N ^a   Bonnefoy, Jean Yves ^a   Bouveret le Cam, Nancy ^a   Corvaïa, Nathalie ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

BBG2Na, elderly; Passive transfer; Respiratory syncytial virus

Indexed keywords

EPITOPE; GUANINE NUCLEOTIDE BINDING PROTEIN; PLACEBO; RECOMBINANT PROTEIN; SUBUNIT VACCINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DILUTION; DOSE RESPONSE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; LOWER RESPIRATORY TRACT INFECTION; LUNG; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS TITRATION;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 0036928450     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2002.1563     Document Type: Article

References (29)

1. Collins, P. L., McIntosh, K., and Chanock, R. M. (1996). Respiratory Syncytial Virus. In "Fields Virology" (B. N. Fields, D. N. Knipe, P. M. Howley, et al., Eds.), pp. 1313-1351. Lippincott-Raven Publishers, Philadelphia.
2. Corbeil, S., Seguin, C., and Trudel, M. (1996). Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2. Vaccine 149, 521-525.
3. Corvaia, N., Tournier, P., Nguyen, T. N., et al. (1997). Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2Na, in aluminum hydroxide. J. Infect. Dis. 176, 560-569.
4. Dowell, S. F., Anderson, L. J., Gary, H. E., et al. (1996). Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infect. Dis. 174, 456-462.
5. Falsey, A. R., Cunningham, C. K., Barker, W. H., et al. (1995). Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. 172, 389-394.
6. Gessner, B. D. (2000). The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly. Vaccine 18, 1485-1494.
7. Goestch, L., Plotnicky-Gilquin, H., Champion, T., et al. (2000). Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na. Vaccine 18, 2648-2655.
8. Hall, C. B., Walsh, E. E., Long, C. E., and Schnabel, K. C. (1991). Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163, 693-698.
9. Han, L. L., Alexander, J. P., and Anderson, L. J. (1999). Respiratory syncytial virus pneumonia among the elderly: An assessment of disease burden. J. Infect. Dis. 179, 25-30.
10. Henderson, F. W., Collier, A. M., Clyde, Jr., W. A., and Denny, F. W. (1979). Respiratory-syncytial-virus infections, reinfections and immunity: A prospective, longitudinal study in young children. N. Engl. J. Med. 300, 530-534.
11. Kahn, J. S. (2000). Respiratory syncytial vaccine development. Curr. Opin. Pediatr. 12, 257-262.
12. LeCam, N. B., Nguyen, T. N., Corvaia, N., et al. (2000). Safety and Immunogenicity of BBG2Na a RSV Subunit Vaccine Based on G Derived Recombinant Protein in the Elderly: A Phase II Study. In 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [abstract]. Toronto, Canada. Washington, DC: American Society for Microbiology. Sept 2000, No. 740.
13. Libon, C., Corvaïa, N., Haeuw, J. F., et al. (1999). The serum albumin-binding region of Streptococcal protein G (BB) potentiates the immunogenicity of the G133-230 RSV-A protein. Vaccine 17, 406-414.
14. Meguro, H., Kervina, M., and Wright, P. F. (1979). Antibody-dependent cell-mediated cytotoxicity against cells infected with respiratory syncytial virus: Characterization of in vitro and in vivo properties. J. Immunol. 122, 2521-2526.
15. Murby, M., Samuelsson, E., Nguyen, T. N., et al. (1995). Hydrophobicity engineering to increase solubility and stability of a recombinant protein from respiratory syncytial virus. Eur. J. Biochem. 230, 38-44.
16. Plotnicky-Gilquin, H., Huss, T., Aubry, J. P., et al. (1999a). Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment. Virol. 258, 128-140.
17. Plotnicky-Gilquin, H., Goetsch, L., Huss, T., et al. (1999b). Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein. J. Virol. 73, 5637-5645.
18. Power, U. F., Plotnicky-Gilquin, H., Huss, T., et al. (1997). Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virol. 230, 155-166.
19. Power, U. F., Nguyen, T., Rietveld, E., et al. (2001). Safety and Immunogenicity of a novel recombinant respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J. Infect. Dis. 184, 1456-1460.
20. Prince, G. A., Hemming, V. G., Horswood, R. L., and Chanock, R. M. (1985). Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rats. Virus Res. 3, 193-206.
21. Reed, L. J., and Muench, H. (1938). A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-497.
22. Shay, D. K., Holman, R. C., Newman, R. D., Liu, L. L., Stout, J. W., and Anderson, L. J. (1999). Bronchiolitis-associated hospitalizations among U.S. children, 1980-1996. JAMA 282, 1440-1446.
23. Shay, D. K., Holman, R. C., Roosevelt, G. E., Clarke, M. J., and Anderson, L. J. (2000). Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among U.S. children, 1979-1997. J. Infect. Dis. 183, 16-22.
24. Siegrist, C. A., Plotnicky-Gilquin, H., Cordova, M., et al. (1999). Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: Influence of adjuvants and maternal antibodies. J. Infect. Dis. 179, 1326-1333.
25. Sigurs, N., Bjamason, R., Sigubersson, F., Kjellman, B., and Bjorksten, B. (1995). Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: A prospective cohort study with matched controls. Pediatrics 95, 500-505.
26. Sommerville, R. G. (1963). Respiratory syncytial virus in acute exacerbations of chronic bronchiolitis. Lancet 2, 1247-8.
27. Trudel, M., Power, U. F., Stahl, S., Bonnefoy, J. Y., and Nguyen, T. N. (2000). Immunogenicity and protective efficacy of a RSV subunit vaccine candidate BBG2Na in African Green Monkeys. In 38th Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [abstract]. San Diego, CA. Sept 1988, No. H-77.
28. Weksler, M. E. (2000). Changes in the B-cell repertoire with age. Vaccine 18, 1624-1628.
29. Zambon, M. (1999). Active and passive immunisation against respiratory syncytial virus. Rev. Med. Virol. 9, 227-236.